trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adenocarcinoma, Papillary D000231 2 associated lipids
Adrenoleukodystrophy D000326 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Asthma D001249 52 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Yáñez RJ and Porter AC A chromosomal position effect on gene targeting in human cells. 2002 Nucleic Acids Res. pmid:12433992
Kishikawa S et al. Roles of histone acetylation in the Dnmt1 gene expression. 2002 Nucleic Acids Res. Suppl. pmid:12903179
Kishikawa S et al. Control elements of Dnmt1 gene are regulated in cell-cycle dependent manner. 2003 Nucleic Acids Res. Suppl. pmid:14510503
Cowell IG et al. Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin. 2011 Jan-Feb Nucleus pmid:21647300
Pérez-Garrastachu M et al. Nucleoporins redistribute inside the nucleus after cell cycle arrest induced by histone deacetylases inhibition. 2017 Nucleus pmid:28696859
Usami M et al. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. 2008 Nutr Res pmid:19083427
Aoyama M et al. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. 2010 Nutrition pmid:20004081
Miyoshi M et al. Short-chain fatty acids and trichostatin A alter tight junction permeability in human umbilical vein endothelial cells. 2008 Nov-Dec Nutrition pmid:18723323
Acun T et al. PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas. 2015 OMICS pmid:25831062
Acun T et al. HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer. 2017 OMICS pmid:28481734
Wang LG et al. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. 2004 Oncogene pmid:15156193
Suzuki M et al. Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b. 2006 Oncogene pmid:16331260
Guo WH et al. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. 2002 Oncogene pmid:12447699
Cao K et al. Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. 2015 Oncogene pmid:25745993
Su SF et al. miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. 2013 Oncogene pmid:23085757
Ong DC et al. LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer. 2009 Oncogene pmid:19734946
Tessema M et al. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. 2010 Oncogene pmid:20562917
Deroanne CF et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. 2002 Oncogene pmid:11821955
Ego T et al. The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression. 2002 Oncogene pmid:12370815
Konduri SD et al. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. 2003 Oncogene pmid:12881707
Mulholland NM et al. Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation. 2003 Oncogene pmid:12894222
Augenlicht L et al. Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. 2003 Oncogene pmid:12902981
Quan H et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. 2014 Oncogene pmid:23770846
Wu Y et al. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. 2001 Oncogene pmid:11313951
Rashid SF et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. 2001 Oncogene pmid:11313934
Krämer OH et al. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. 2008 Oncogene pmid:17653085
Lu Z et al. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. 2006 Oncogene pmid:16158053
Pulukuri SM et al. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. 2009 Oncogene pmid:19503093
Cras A et al. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. 2007 Oncogene pmid:17213810
Karagiannis TC et al. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. 2007 Oncogene pmid:17213813
Toyooka S et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. 2002 Oncogene pmid:12082623
Nishikata I et al. Sumoylation of MEL1S at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced myeloid differentiation. 2011 Oncogene pmid:21516122
Jang ER et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. 2004 Oncogene pmid:14676837
Campanero MR et al. The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites. 2008 Oncogene pmid:17724474
Zhong S et al. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. 2007 Oncogene pmid:17043644
López-Soto A et al. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. 2009 Oncogene pmid:19430493
Reid G et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. 2005 Oncogene pmid:15870696
Sengupta S et al. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. 2011 Oncogene pmid:20856196
Kim YB et al. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. 1999 Oncogene pmid:10229197
Usenko T et al. Transient expression of E1A and Ras oncogenes causes downregulation of c-fos gene transcription in nontransformed REF52 cells. 2003 Oncogene pmid:14576829
Suzuki M et al. Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. 2003 Oncogene pmid:14647463
Coombes MM et al. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. 2003 Oncogene pmid:14654786
Chan AS et al. Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. 2003 Oncogene pmid:14534543
Krishnan M et al. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. 2010 Oncogene pmid:19881542
Duan H et al. Functional long-range interactions of the IgH 3' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells. 2008 Oncogene pmid:18695675
Meng Z et al. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. 2016 Oncogene pmid:26279303
Ibanez de Caceres I et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. 2010 Oncogene pmid:20023704
Lund P et al. Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. 2006 Oncogene pmid:16568090
Lee SH et al. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. 2009 Oncogene pmid:18850007
Baraz L et al. Tumor suppressor p53 regulates heparanase gene expression. 2006 Oncogene pmid:16474844